Literature DB >> 12086295

Renal effects of nonselective NSAIDs and coxibs.

Matthew R Weir1.   

Abstract

Despite the ubiquitous use of both over-the-counter and prescription nonsteroidal anti-inflammatory drugs (NSAIDs), clinical syndromes-NSAID-related hypertension, salt and water retention, edema, and hyperkalemia-are highly infrequent. Nevertheless, they remain a concern, and patient populations at risk for renal adverse effects from NSAIDs can be prospectively identified. Patients at risk include those with age-related declines in glomerular filtration rate; those with hypovolemia, particularly patients taking loop diuretics; and those with congestive heart failure, cirrhosis, or nephrosis. The following patient populations are at higher risk for increases in blood pressure with concomitant use of an NSAID and an antihypertensive: those with congestive heart failure, liver disease, or kidney disease, and those taking angiotensin-converting enzyme inhibitors or diuretics. Nonselective NSAIDs and COX (cyclooxygenase)-2-selective inhibitors (coxibs) appear to have similar effects on renal function if dosed equivalently, and standard precautions to avoid renal toxicity with use of nonselective NSAIDs apply to coxibs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086295     DOI: 10.3949/ccjm.69.suppl_1.si53

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  28 in total

1.  Evaluating the effects of diclofenac sodium and etodolac on renal hemodynamics with contrast-enhanced ultrasonography: a pilot study.

Authors:  Hiroshi Imamura; Jiro Hata; Ai Iida; Noriaki Manabe; Ken Haruma
Journal:  Eur J Clin Pharmacol       Date:  2012-06-26       Impact factor: 2.953

2.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

Review 3.  Palliative care for patients with end-stage liver disease.

Authors:  Anne M Larson
Journal:  Curr Gastroenterol Rep       Date:  2015-05

4.  Tinospora cordifolia inhibits autoimmune arthritis by regulating key immune mediators of inflammation and bone damage.

Authors:  K M Sannegowda; S H Venkatesha; K D Moudgil
Journal:  Int J Immunopathol Pharmacol       Date:  2015-10-14       Impact factor: 3.219

Review 5.  Palliative care for end-stage heart failure.

Authors:  Sarah J Goodlin
Journal:  Curr Heart Fail Rep       Date:  2005-09

6.  Fibromuscular dysplasia presenting with asymptomatic bilateral renal infarctions.

Authors:  J González-Moreno; M A Campins; J M Buades
Journal:  Int Urol Nephrol       Date:  2013-01-06       Impact factor: 2.370

Review 7.  Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms.

Authors:  Rodger Loutzenhiser; Karen Griffin; Geoffrey Williamson; Anil Bidani
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-05       Impact factor: 3.619

8.  Huo-Luo-Xiao-Ling Dan modulates antigen-directed immune response in adjuvant-induced inflammation.

Authors:  Rajesh Rajaiah; David Y-W Lee; Zhongze Ma; Arthur Y Fan; Lixing Lao; Harry H S Fong; Brian M Berman; Kamal D Moudgil
Journal:  J Ethnopharmacol       Date:  2009-03-04       Impact factor: 4.360

Review 9.  End-of-life care in heart failure.

Authors:  Sarah J Goodlin
Journal:  Curr Cardiol Rep       Date:  2009-05       Impact factor: 2.931

Review 10.  N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence.

Authors:  Hesamoddin Hosseinjani; Azadeh Moghaddas; Hossein Khalili
Journal:  Eur J Clin Pharmacol       Date:  2013-03-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.